In
the radiolabelling process, the frequency of routine analytical testing must be
defined with a risk assessment based on different factors (Pharmeuropa Vol. 26
No. 2, 5.19). Aim of this study is to define the criteria based on the risk
assessment required for setting the frequency of analytical controls. 331 preparations
of three different radiopharmaceuticals labeled with 99mTc were
examined analyzing temporal trends of radiochemical purity values, potential
correlation between radiochemical purity values and total radioactivity content
of bulk as well as potential correlation between radiochemical purity values
and radioactivity concentration of bulk. The analysis shows no direct
correlation between percentage of radiochemical purity and total radioactivity
content of preparation and between radiochemical purity values and
radioactivity concentration in final bulk solution. Moreover, the routine
analytical controls executed for one year on each preparation made it possible
to determine how the analytical values do not have inter-operator dependency
and there is no evidence of specific temporal trends over time. The study is
aimed to assess any eventual criticality related with radiochemical purity
tests, determine the possibility of a parametric release and the optimal
frequency of tests, without reducing the level of safety of the preparations.
This will produce a substantial reduction of costs and of radiation exposure to
ionizing radiation of the staff dedicated to Quality Control procedures.
Cite this paper
Ria, F. , Albini, G. , Battista, S. , Salvatore, V. , Messere, R. , Bergantin, A. , Redaelli, I. , Bonfanti, P. , Martinotti, A. S. , Gandolfo, P. and Papa, S. (2017). Study to Define Frequency in Routine Analytical Controls in the Radiolabelling Process. Open Access Library Journal, 4, e3602. doi: http://dx.doi.org/10.4236/oalib.1103602.
The
Ministry of Health (2005) Approvazione Primo Supplemento alla XI Edizione
della Farmacopea Ufficiale della Repubblica Italiana. Repubblica Italiana Decreto
del Ministero della Salute 30 marzo 2005, Decree of the Italian
Republic.
Walters, L.R.,
Martins,
K.J., et al. (2012) Stability
Evaluation of (18) F-FDG at High Radioactive Concentrations. Journal of Nuclear Medicine Technology, 40, 52-56. https://doi.org/10.2967/jnmt.111.097287
European
Commission (2008)
Manufacture of Sterile Medicinal Products, Annex 1 EudraLex Volume 4 Good
Manufacturing Practice (GMP) Guidelines. European Commission, Brussels,
Belgium.
Chittò,
G.,
Domenico, E.D.,
Gandolfo, P., Ria,
F.,
Tafuri, C. and Papa,
S. (2013) Risk Assessment and
Economic Impact Analysis of the Implementation of New European Legislation on Radiopharmaceuticals
in Italy: The Case of the New Monograph Chapter Compounding of
Radiopharmaceuticals (PHARMEUROPA, Vol. 23, No. 4, October 2011). Current
Radiopharmaceutical, 6.
Delacroix,
D.,
Guerre, J.P.,
Leblanc, P.
and Hickman,
C. (2002) Radionuclide
and Radiation Protection Data Handbook, 2nd Edition. Radiation Protection Dosimetry, 98,
9-18.